When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Magenta Therapeutics (NASDAQ:MGTA) has completed dosing in its Phase 1 trial of stem cell mobilization therapy clinical candidate, MGTA-145, as well as updated clinical data from the trial at the Transplant and Cellular Therapy Annual Meeting in Orlando, Florida.
More news on: Magenta Therapeutics, Inc., Healthcare stocks news,